General Information of DTT (ID: TTWELHI)

DTT Name Stress-activated protein kinase (p38) DTT Info
Gene Name p38

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Clinical Trial Drug(s)
9 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-07265803 DM3E6Q4 Dilated cardiomyopathy BC43.0 Phase 3 [1]
ARRY-797 DMJ48AB Dilated cardiomyopathy BC43.0 Phase 2 [2]
AZD7624 DMEW3K9 Chronic obstructive pulmonary disease CA22 Phase 2 [3]
BMS-582949 DMGYXFP Atherosclerosis BD40 Phase 2 [4]
GSK2269557 DMIN0SV Asthma CA23 Phase 2 [5]
MW150 DMBRVXB Alzheimer disease 8A20 Phase 2 [6]
TAK-715 DMZKPI8 Rheumatoid arthritis FA20 Phase 2 [7]
LY-2228820 DMHXTNW Solid tumour/cancer 2A00-2F9Z Phase 1/2 [8]
PUR1800 DM6H10N Chronic obstructive pulmonary disease CA22 Phase 1 [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Clinical Trial Drug(s)
6 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARRY-614 DMXD93K Arthritis FA20 Discontinued in Phase 1 [10]
AVE-9940 DMIB3AT Rheumatoid arthritis FA20 Discontinued in Phase 1 [11]
AZD-6703 DM9KLD3 Rheumatoid arthritis FA20 Discontinued in Phase 1 [12]
SB-281832 DMYTAJW Asthma CA23 Discontinued in Phase 1 [13]
TA-5493 DMFES2K Inflammation 1A00-CA43.1 Discontinued in Phase 1 [14]
AMG-548 DMYIPLH Inflammation 1A00-CA43.1 Terminated [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Discontinued Drug(s)
Molecule Interaction Atlas

References

1 Clinical pipeline report, company report or official report of Pfizer
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
4 Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.
5 Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70.
6 p38alpha MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10245-E10254.
7 Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959).
9 Clinical pipeline report, company report or official report of Pulmatrix Lexington, MA
10 Cmpany report (Arraybiopharma)
11 US patent application no. 2008,0119,498, Therapeutic agent for pruritus comprising p38 map kinase inhibitor as the active ingredient.
12 The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3879-83.
13 p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther. 2003 Dec;307(3):932-8.
14 US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.
15 p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel. 2005 Jul;8(4):421-30.